Global Artificial Intelligence in Genomics Market Overview
As per MRFR analysis, the Artificial Intelligence in Genomics Market Size was estimated at 2.38 (USD Billion) in 2022.
The Artificial Intelligence in Genomics Market Industry is expected to grow from 3.17(USD Billion) in 2023 and USD 4.23 billion in 2024 to 42.6 (USD Billion) by 2032. The Artificial Intelligence in Genomics Market CAGR (growth rate) is expected to be around 33.46% during the forecast period (2023 - 2032).
Key Artificial Intelligence in Genomics Market Trends Highlighted
Genomics has revolutionized healthcare by providing profound insights into an individual's genetic makeup. The fusion of artificial intelligence (AI) with genomics has further enhanced the field, enabling the analysis of vast genetic data sets and advanced precision medicine. The global market for AI in genomics is poised for exponential growth, projected to reach USD 42.6 billion by 2032, driven by a CAGR of 33.46%.
The increasing incidence of chronic diseases, growing healthcare spending, advancement of gene sequencing technologies, and government promotion of personalized medicine are significant market drivers. Researchers and doctors can use artificial intelligence to find genetic variations behind ailments, foreseeing the likelihood of their occurrences and characterizing a particular treatment for each patient.
AI is widely used in genomics for drug discovery, personalized medicine, and disease diagnostics. With AI tools that evaluate potential new drug targets, model how well drugs will work before they are tested on people, or optimize treatment strategies. Genomic diagnostics with the integration of AI improve accuracy and accelerate speed, as well as provide an early identification platform for genetic disorders. Recent developments have led to AI-supported genetic counseling, which uses natural language processing techniques to provide tailored information for patients and families.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Artificial Intelligence in Genomics Market Drivers
-
The Rise of Precision Medicine
The field of medical research has been revolutionized by personalized medicine, which also accounts for genetic and environmental differences that affect people’s well-being. This meaningfulness is attainable by the utilization of Artificial Intelligence in Genomics to mine vast and intricate data sets, thereby enabling pattern identification for future predictions in the Global Artificial Intelligence in the Genomics Industry. With this, AI can be implemented to scrutinize genomic data to identify disease risk factors, predict drug response, and develop individualized care plans. For example, there have been some remarkable developments in cancer treatments and cardiovascular diseases, among others, courtesy of AI (Artificial Intelligence). Thus, it is expected that AI will continue to play a major role in precision medicine, hence facilitating global artificial intelligence in the genomics market.
-
Growing Adoption of Cloud-Based Solutions
Like other industries, health care has also increasingly depended on cloud-based solutions. The use of cloud computing is beneficial in terms of scalability, adaptability, and low costs. This makes it possible for healthcare providers to access and evaluate huge amounts of information without having to spend too much on building the required onsite setup, which promotes better patient care. However, in the Genomics Artificial Intelligence industry, it is used for genomics data storage and management.
This has, therefore, made it easy for scientists and doctors to work together on different projects and share data, leading to quick and efficient drug discovery and development. This is because as long as there is growth in demand, Cloud-Based Solutions will always increase the adoption of such models within Artificial Intelligence applications.
-
Increasing Availability of Genetic Data
Recently, there has been a large decline in the cost of sequencing the human genome, which has made it more convenient for researchers and physicians. The outcome has been an increase in the amount of genetic information available, leading to the birth of new genomics analysis tools that use AI. The global market for AI in genomics. This is particularly important for the personalized medicine sector, which has improved its accessibility to genetic data.
They can tell if someone might be susceptible to any particular disease on the basis of their DNA and may even recommend the best methods for treatment. This data would be useful when developing patient-centered plans that lead to better healthcare outcomes while minimizing medical expenditure.
Artificial Intelligence in Genomics Market Segment Insights
Artificial Intelligence in Genomics Technology Insights
Global artificial intelligence (AI) technology in the genomics market segment encompasses machine learning, computer vision, deep learning, natural language processing (NLP), and robotic process automation (RPA). Machine learning (ML) is a category of AI where computers learn without explicit programming. This is used to identify patterns and make predictions in genomics with huge data sets. For example, it can be employed to identify genetic variations that are linked to diseases or determine how an individual would respond to a given drug.
The global ML in Genomics market is expected to grow from USD 1.2 billion in 2023 to USD 10.5 billion by 2032, at a CAGR of 31.5%. Deep Learning (DL) is a type of ML that uses artificial neural networks to learn from data. DL is used in genomics to analyze complex data, such as images and sequences. For example, DL can be used to identify genetic variants associated with diseases or to predict the response of a patient to a particular treatment. The global DL in the Genomics market is expected to grow from USD 0.8 billion in 2023 to USD 7.2 billion by 2032 at a CAGR of 30.2%.
NLP is a form of AI enabling machines to read and write in human language. In Genomics, NLP is used to obtain knowledge from texts like medical reports and scientific publications. For instance, NLP could detect genetic variants implicated in diseases or forecast how a patient will respond to treatment. The global NLP in the Genomics market is anticipated to grow at a CAGR of 29.1%, from $0.6 billion in 2023 to $5.1 billion by 2032.
CV is one type of AI that helps computers see and understand images.
CV aids in the examination of microscopic images and x-rays, among others done in genomics, such as through computer vision. The examples include identifying genetic variations associated with diseases or predicting probable responses of patients towards therapy. Global CV within the Genomics market has an estimated CAGR of 28% between 2023, when it would have been valued at $0.5bn, and 2032, when it will be projected at $4.2bn.
RPA is an AI type that allows computers to automatically run repetitive tasks on their own. RPA has applications that include data entry, cleaning, and analysis, such as those carried out by humans.
For example, RPA can be employed to automate the identification of genetic variants linked with diseases or predict patients’ responsiveness toward their medication. The global RPA in the Genomics market is projected at a CAGR of 27% from $0.4 bn in 2023 to $3 bn by 2032.
This growth has come about because artificial intelligence (AI) technology has been adopted by healthcare companies that want high-quality genome detection systems, thus leading to clinical strategies being developed based on them.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Artificial Intelligence in Genomics End User Insights
Artificial Intelligence in Genomics Market End-User Segment Includes Pharmaceutical Companies, Biotechnology Companies, Academic Institutions, CDMOs & CROs and Others. Among these, the highest market share will be held by pharmaceutical companies with a revenue of 12.67 Billion USD by 2024, implying a substantial increment. Biotech companies also have high market shares, with revenues projected to achieve $8.9 billion in 2024. Growth is driven by academic institutions engaged in research and development.
As a result, hospitals and clinics are embracing AI-driven genomics solutions aimed at enhancing patient care, thereby increasing demand for this market. Furthermore, government agencies fund research projects and regulate AI use in genomics, thus shaping the said dynamics.
Artificial Intelligence in Genomics Deployment Model Insights
The Artificial Intelligence in Genomics Market’s deployment model segment is generally categorized into on-premises, cloud-based, and hybrid. The future share of the market should be significant in the cloud-based sector, among others. Cloud computing services are increasingly being adopted due to their growing popularity, scalability, flexibility, and cost-effectiveness, thus leading to the evolution of the cloud-based deployment model. Nonetheless, some institutions are still focusing on data security and control; therefore, they prefer the on-premises model, which is expected to increase at a slow pace in the future.
Also, there is an emerging concern with the hybrid deployment model combining the benefits of both on-premises and cloud-based models, giving businesses a choice to deploy as per their needs.
Artificial Intelligence in Genomics Regional Insights
The largest market share in 2023 was held by North America, which is likely to persist through the forecast period. This is because of the strong healthcare infrastructure in the region and the industry majors that are at the forefront of adopting AI technologies. Europe is another major market as its governments are pushing for the adoption of AI in genomics research and healthcare. APAC will see the highest growth rate due to increasing medical spending, coupled with growing awareness about AI technology and increased investment in genomics research.
In South America and MEA, there are emerging markets where genomics AI has the potential for growth.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Artificial Intelligence in Genomics Market Key Players and Competitive Insights
Continuous innovation and adoption of new technologies aim to give major players an edge in the AI genomics industry. The AI in Genomics market’s top firms spends much on conducting R&D to solve genomic-related issues. In addition, they form alliances with other business entities or come up with partnerships that will enable them to increase their product line as well as expand their customer base. Competition for Artificial Intelligence in Genomics Market changes quickly as new entrants enter, and these new players generally focus on particular applications, thereby creating niche areas.
One of the dominant participants within AI in genomics market is Illumina Inc. It has various products, including sequencing and genotyping, among others, used by researchers and clinicians from different disciplines, such as clinical research. This continuous interest in invention has maintained it as a leading company in that market over time. Another key player is Thermo Fisher Scientific, which specializes mostly in genetic analysis instruments, reagents, and software, among other things like THERMO FISHER SCIENTIFIe.
Other important players apart from Illumina and Thermo Fisher Scientific are Pacific Biosciences of California, Inc., QIAGEN, Agilent Technologies, etc. These firms have introduced groundbreaking solutions for furthering advancements in knowledge about genomics. There are expected to be intense competitive dynamics across artificial intelligence for genomics markets during this period, with innovations occurring at midnight, and there will be increasing entry barriers through shifts in vendor relationships.
Key Companies in the Artificial Intelligence in Genomics Market Include:
- Abcam
- Oxford Nanopore Technologies
- Qiagen
- Adaptive Biotechnologies
- Illumina
- Invitae
- NeoGenomics
- Agilent
- Bruker
- 10x Genomics
- Caris Life Sciences
- Guardant Health
- PerkinElmer
- Foundation Medicine
- BioRad Laboratories
Artificial Intelligence in Genomics Market Industry Developments
The Artificial Intelligence in Genomics Market is experiencing robust growth, driven by advancements in AI algorithms, increasing adoption of precision medicine, and growing investments in genomics research. In 2023, the market was valued at approximately USD 3.17 billion, and it is projected to reach USD 42.6 billion by 2032, exhibiting a CAGR of 33.46%. Illumina, Inc., Agilent Technologies, Inc., QIAGEN, and Thermo Fisher Scientific, Inc. are key players in the industry.
Some of the recent developments include AI-based genomic analysis platforms launched by companies like Google DeepMind as well as collaborations between AI companies and genomics research institutes; AI integration in clinical decision support systems is another notable development. The market is expected to grow significantly over the next few years due to the rise in personalized medications, cloud computing advancements, and increasing use of AI in healthcare.
Artificial Intelligence in Genomics Market Segmentation
Artificial Intelligence in Genomics Technology Outlook
- Machine Learning
- Deep Learning
- Natural Language Processing
- Computer Vision
- Robotic Process Automation
Artificial Intelligence in Genomics Application Outlook
- Diagnostics
- Drug Discovery and Development
Artificial Intelligence in Genomics End User Outlook
- Pharmaceutical Companies
- Biotechnology Companies
- Academic Institutions
- CDMOs and CROs
- Others
Artificial Intelligence in Genomics Deployment Model Outlook
- On-premises
- Cloud-based
- Hybrid
Artificial Intelligence in Genomics Function Outlook
- Functional Genomics Analysis
- Predictive Genomics Analysis
- Structural Genomics Analysis
- Others
Artificial Intelligence in Genomics Regional Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
| Report Attribute/Metric |
Details |
| Market Size 2022 |
2.38(USD Billion) |
| Market Size 2023 |
3.17(USD Billion) |
| Market Size 2032 |
42.6(USD Billion) |
| Compound Annual Growth Rate (CAGR) |
33.46% (2023 - 2032) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year |
2023 |
| Market Forecast Period |
2023 - 2032 |
| Historical Data |
2019 - 2023 |
| Market Forecast Units |
USD Billion |
| Key Companies Profiled |
Abcam ,Oxford Nanopore Technologies ,Qiagen ,Adaptive Biotechnologies ,Illumina ,Invitae ,NeoGenomics ,Agilent ,Bruker ,10x Genomics ,Caris Life Sciences ,Guardant Health ,PerkinElmer ,Foundation Medicine ,BioRad Laboratories |
| Segments Covered |
Technology ,Application ,End User ,Deployment Model ,Data Type ,Regional |
| Key Market Opportunities |
Precision medicine Drug discovery Personalized treatments Disease diagnosis Genomic data analysis |
| Key Market Dynamics |
1 Growing adoption of AI in healthcare2 Increasing genomics data volume3 Advancements in machine learning algorithms4 Government initiatives supporting AI in genomics5 Rising demand for personalized medicine |
| Countries Covered |
North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Artificial intelligence in the genomics market was worth 3.17 billion USD in 2023
The Artificial Intelligence in Genomics Market may achieve USD 42.6 billion by 2032.
The artificial intelligence in genomics market’s CAGR has been projected at 33.46% between 2023 and 2032.
North America will be in a leading position; Europe and Asia-Pacific are right behind it as regions having larger shares than others both compete closely for leadership of this market category.
Key players like Thermo Fisher Scientific, Illumina, and QIAGEN are competing with each other for dominance over AI-based genomic tools.
Besides data privacy & security concerns, skilled workforce shortage is another important challenge faced by the industry offering AI-based genomic tools such as drug discovery tools or genetic testing kits.
Factors such as rising volumes of genomic data, increasing demand for personalized medicine application programming interfaces (APIs), and innovations driven through artificial intelligence techniques are accountable for driving growth within this sector.
Opportunities that exist in the artificial intelligence in the genomics market include entry into novel markets, new AI-driven genomic tools, and partnerships between healthcare providers and AI companies.
Over time, machine learning and deep learning techniques have made a great impact on this sector; lately, the growing adoption of cloud-based AI solutions has shown promise for improved patient healthcare outcomes through precision medicine use cases.
